Abstract
Objective Little is known about the prevalence and clinical presentation of avoidant restrictive food intake disorder (ARFID) in preschool children, and well-validated, parent-reported screening tools are lacking. This study evaluated the diagnostic validity of the parent-reported ARFID-Brief Screener in preschool children and examined prevalence and clinical characteristics of ARFID.
Method Parents of 645 children (50.5% male, mean age 3.2 years) completed the ARFID-Brief Screener in connection with the 2.5- and 4-year routine check-ups at 21 child health services centers in West Sweden. Parents of all screen-positive and of randomly selected screen-negative children were invited to a clinical follow-up interview via phone. Co-occurring neurodevelopmental problems were assessed via questionnaire, clinical examination, and health care records.
Results Of 42 (6.5%) children screening positive for ARFID, 29 were followed up via interview, and ARFID diagnosis was confirmed in 21 (positive predicted value 72%; other diagnostic metrics: negative predictive value 94%, sensitivity 91%, specificity 79%, and overall accuracy 84%. The adjusted prevalence of ARFID was 5.9%. All children with ARFID presented with both sensory-based avoidance and low interest, and the majority (65.2%) met criteria solely through DSM-5 criterion A4 (marked interference with psychosocial functioning). The ARFID group had significantly more co-occurring neurodevelopmental problems.
Discussion ARFID is not rare among preschoolers, although prevalence might have been slightly overestimated here. The ARFID–Brief Screener showed high diagnostic validity, but follow-up assessments are necessary to confirm diagnoses and reduce false positives. Co-occurring neurodevelopmental problems were common in ARFID and may serve as early markers of increased ARFID risk.
Public Significance Statement This study provides valuable insights into the occurrence of avoidant restrictive food intake disorder (ARFID) in preschool children, a group previously underrepresented in research. Our findings support the effectiveness of the ARFID-Brief Screener in identifying at-risk children, potentially enabling timely interventions and improving long-term outcomes. The higher prevalence of early-onset neurodevelopmental problems in children with ARFID suggest that they may serve as early markers of increased risk of ARFID.
Competing Interest Statement
LD: reports speaker fees from Baxter Medical AB and Fresenius Kabi AB. Other authors have no conflict to declare.
Funding Statement
Swedish Research Council (Vetenskapsradet; Rastam, 2018-02544; Gillberg, 538-2013-8864); Swedish Brain Foundation (Hjarnfonden) with support from Ulf Lundahls Minnesfond, Susanne Hobohms Stiftelse, and Team Rynkeby (Rastam, FO2020-0140, FO2022-0094); Japan Society for the Promotion of Science KAKENHI (Fujieda, JP18KK0263); Professor Bror Gadelius Memorial Foundation (Dinkler, 2019, 2020); AnnMari and Per Ahlqvist Foundation (Gillberg, 2018). The funding bodies were not involved in the design of the study; collection, analysis, interpretation of the data; or writing of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Swedish Ethical Review Authority gave ethical approval for this work(Dnr 2020-01284, 2020-03908, 2021-01849).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
* Email addresses & ORCIDs katarzyna.brimo{at}gu.se, helena.holmang{at}gu.se, kahoko.yasumitsu-lovell{at}kochi-u.ac.jp, ralf.kuja-halkola{at}ki.se, anne-katrin.kantzer{at}socialstyrelsen.se, zerina.omanovic{at}vgregion.se, fujiedam{at}kochi-u.ac.jp, nsuganuma{at}kochi-u.ac.jp, meitoku{at}kochi-u.ac.jp, elisabeth.fernell{at}gnc.gu.se, info{at}skolhalsovard.com, Rachel.Bryant-Waugh{at}slam.nhs.uk, christopher.gillberg{at}gnc.gu.se, maria.rastam_bergstrom{at}med.lu.se
Data Availability
All data produced in the present study are available upon reasonable request to the authors